, GBD Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study, Lancet, vol.385, issue.9963, pp.117-171, 2013.

P. Observatory and H. Collaborators, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study, Lancet Gastroenterol Hepatol, vol.2, issue.3, pp.161-176, 2017.

, Towards the elimination of hepatitis B and C by 2030, 2016.

, World Health Organisation. Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection. Updated version, 2016.

P. K. Nelson, B. M. Mathers, and B. Cowie, Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews, Lancet, vol.378, issue.9791, pp.571-583, 2011.

, United Nations Office on Drugs and Crime. Afghan opiate trafficking through the Southern route

, United Nations Office on Drugs and Crime. Transnational Organised Crime in East Africa: A Threat Assessment, vol.2013, p.4

, New treatment gives hope to East Africa's drug users, Bull World Health Organ, vol.91, pp.89-90, 2013.

A. Lepretre, I. Ba, and K. Lacombe, Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study, J Int AIDS Soc, vol.18, 2015.

A. L. Bowring, N. Luhmann, and S. Pont, An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Int J Drug Policy, vol.24, issue.1, pp.78-81, 2011.

M. Odek-ogunde, . Seroprevalence, and . Hiv, World Health Organisation drug injecting study Phase II Findings, HBV and HCV in injecting drug users in, 2004.

B. H. Lambdin, J. Lorvick, and J. K. Mbwambo, Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania, Int J Drug Policy, vol.45, pp.64-69, 2017.

M. Thursz and K. Lacombe, Breaking down barriers to care in hepatitis C virus infection, J Infect Dis, vol.213, issue.7, pp.1055-1056, 2016.

P. Bonnard, A. Elsharkawy, and K. Zalata, Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt, J Viral Hepat, vol.22, issue.3, pp.245-253, 2015.

Y. Shimakawa, P. Bonnard, E. Kassas, M. , A. et al., Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4, Gut, vol.65, issue.9, pp.1577-1578, 2016.

M. Lemoine, Y. Shimakawa, and S. Nayagam, The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa, Gut, vol.65, issue.8, pp.1369-1376, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-02875304

J. O. Smith and R. K. Sterling, Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C, Aliment Pharmacol Ther, vol.30, issue.6, pp.557-576, 2009.

L. Sandrin, B. Fourquet, and J. M. Hasquenoph, Transient elastography: a new noninvasive method for assessment of hepatic fibrosis, Ultrasound Med Biol, vol.29, issue.12, pp.1705-1713, 2003.

J. Boursier, J. P. Zarski, and V. De-ledinghen, Determination of reliability criteria for liver stiffness evaluation by transient elastography, Hepatology, vol.57, issue.3, pp.1182-1191, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02517170

J. P. Bronowicki, D. Ouzan, and T. Asselah, Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin, Gastroenterology, vol.131, issue.4, pp.1040-1048, 2006.

T. Muasya, W. Lore, and K. Yano, Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya, East Afr Med J, vol.85, issue.7, pp.318-325, 2008.

, United Nations Office on Drugs and Crime. World Drug Report, 2015.

M. G. Collier, S. K. Bhaurla, J. Cuevas-mota, R. F. Armenta, E. H. Teshale et al., Awareness of HCV infection among persons who inject drugs in, Am J Public Health, vol.105, issue.2, pp.302-303, 2015.

J. Bruneau, G. Zang, M. Abrahamowicz, D. Jutras-aswad, M. Daniel et al., Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study, Clin Infect Dis, vol.58, issue.6, pp.755-761, 2014.

T. Roberts, Simplified HCV Diagnostics, 2016.

J. M. Freiman, T. M. Tran, and S. G. Schumacher, Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis, Ann Intern Med, vol.165, issue.5, pp.345-355, 2016.

L. Duchesne, R. Njouom, and F. Lissock, HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study, J Int AIDS Soc, vol.20, issue.1, pp.1-8, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01536669

Z. Mohamed, J. Mbwambo, and Y. Shimakawa, Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in, J Int AIDS Soc, vol.20, issue.1, p.21856, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-02875248

J. Grebely, F. Lamoury, and B. Hajarizadeh, Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncturecollected and finger-stick capillary whole-blood samples: a cohort study, Lancet Gastroenterol Hepatol, vol.2, issue.7, pp.514-520, 2017.

A. D. Marshall, M. Micallef, and A. Erratt, Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study, Int J Drug Policy, vol.26, issue.10, pp.984-991, 2015.

G. D. Kirk, J. Astemborski, and S. H. Mehta, Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection, Clin Infect Dis, vol.48, issue.7, pp.963-972, 2009.

B. K. Moessner, T. R. Jorgensen, and M. Skamling, Outreach screening of drug users for cirrhosis with transient elastography, Addiction, vol.106, issue.5, pp.970-976, 2011.

S. Romeo, J. Kozlitina, and C. Xing, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, vol.40, issue.12, pp.1461-1465, 2008.

A. Johannessen and M. Lemoine, Is aspartate aminotransferase-toplatelet ratio index a reliable tool in human immunodeficiency virus patients in Africa?, Liver Int, vol.35, issue.8, p.2059, 2015.

A. De-weggheleire, A. S. Buyze, J. Thai, S. Lynen, and L. , Usual APRI Score Thresholds Lack Sensitivity to Prioritise for Hepatitis C Treatment in a HCV/HIV Coinfected Cohort in Cambodia, 2017.

N. K. Martin, M. Hickman, S. J. Hutchinson, D. J. Goldberg, and P. Vickerman, Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy, Clin Infect Dis, vol.57, issue.2, pp.39-45, 2013.

B. D. Marshall, T. C. Green, J. L. Yedinak, and S. E. Hadland, Harm reduction for young people who use prescription opioids extra-medically: obstacles and opportunities, Int J Drug Policy, vol.31, pp.25-31, 2016.

J. S. Crowley and G. A. Millett, Preventing HIV and hepatitis infections among people who inject drugs: leveraging an indiana outbreak response to break the impasse, AIDS Behav, vol.21, issue.4, pp.968-972, 2017.

. Medicins-du-monde, Tanzania project summary

, The World Bank, 2016.

, World Health Organisation, 2017.

, World Health Organisation. WHO prequalifies first generic active ingredient for hepatitis C medicines, 2017.

Z. Mohamed, J. Rwegasha, and J. U. Kim, The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, J Viral Hepat, vol.25, pp.1438-1445, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-02875234